23 females, mean age 53 years, with genuine stress incontinence were treated with phenylpropanolamine (PPA), 50 mg twice daily, versus placebo. Simultaneous urethrocystometry with recording of the transmission of increased abdominal pressure to the bladder and the urethra was carried out, and serum concentration of PPA measured and related to subjective effect, effect on the maximal urethral closure pressure (MUCP) and on the pressure transmission ratio. 3 patients were excluded, 1 because of side effects, and 2 were dropouts. 12 patients reported improvement while on PPA, but none became continent. 3 patients improved on placebo. The remaining patients were unchanged. A plasma level of PPA of more than 150 ng/ml seemed necessary to obtain an effect; this level was reached after approximately 90 min after intake of 50 mg. Objectively a rise in MUCP was recorded, but there was no correlation between serum concentration and the increase in MUCP. An improvement of the pressure transmission ratio was also recorded.

Keywords:
Phenylpropanolamine, Stress incontinence, Simultaneous urethrocystometry, Pressure transmission ratio, Alpha stimulation
This content is only available via PDF.
© 1983 S. Karger AG, Basel
1983
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.